National Defense Medical Center

Taipei, Taiwan

National Defense Medical Center

Taipei, Taiwan
SEARCH FILTERS
Time filter
Source Type

Patent
National Defense Medical Center | Date: 2017-09-27

A pharmaceutical composition for treating cancer, the composition comprising: Soraphenib and GW5047 (3-(3,5-dibromo-4-hydroxybenzylidene)-5-iodo-1, 3-dihydroindol-2-one. The combination therapy inhibits growth of cancer cells through a c-Raf-PP2A-DAPK signaling pathway either in an in-vitro model or an in-vivo spontaneous metastasis kidney cancer cells animal model simulating clinical symptoms. After GW5074 forms a bond to c-Raf, the conformation of c-Raf is changed, leading to an increase in affinity between Sorafenib and c-Raf. This special targeted combination of the drug promotes PP2A to dephosphorylate a serine 308 of a DAPK protein such that the cancer cells deteriorate, and the serine 308 of the DPTK protein can also be a biomarker for drug screening.


A method for detecting cardiac status is provided. A users heart rate is measured by a heart rate detection unit, and the users acceleration or activity level is measured by an acceleration detection unit, which the activity level is calculated by the acceleration detection unit. A cardio force index is obtained by a calculating unit based on the heart rate, and the acceleration, or the weight as the following formula (Ia) or (Ib): CFI=(Weight) Acceleration/Heart Rate (Ia) CFI=(Weight) Activity Level/Heart Rate (Ib) The cardio force ratio is a ratio of the user as the following formula (II): Cardio Force Ratio=CFI of Exercise/CFI of Walking (II) A method for monitoring cardiac status during exercise and an apparatus for monitoring cardiac status are also provided.


A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.


Patent
National Defense Medical Center | Date: 2016-04-06

The invention provides a series of novel thiochromeno[2,3-c] quinolin-12-one derivatives (I). Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with treating effective amount are prepared into pharmaceutical compositions for inhibition of topoisomerase type I and II, inhibition of cancer cell growth, further treating cancer.


Patent
National Defense Medical Center | Date: 2015-08-14

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.


A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.


Patent
National Defense Medical Center | Date: 2015-04-22

The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.


Patent
National Defense Medical Center | Date: 2015-01-29

The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II and the synthesis and the application thereof.


Patent
National Defense Medical Center | Date: 2015-04-22

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.


Patent
National Defense Medical Center | Date: 2016-03-07

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,-naphthoflavone, -naphthoflavone, hesperetin, terpineol, (+)-limonene, -myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, ()-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

Loading National Defense Medical Center collaborators
Loading National Defense Medical Center collaborators